Metreleptin in Anorexia Nervosa

Status Not yet recruiting

Clinical Trial Summary

The treatment of anorexia nervosa often proves to be difficult. There are no drugs that work specifically for the treatment of anorexia nervosa. Experimental administration of metreleptin (synthetically produced leptin) to patients with anorexia nervosa has produced positive results. This study tests the effect of metreleptin in comparison with placebo, which could potentially make treatment easier. The aim of the study is to investigate whether treatment with metreleptin can help to reduce the symptoms of anorexia nervosa and improve mood and weight.

Clinical Trial Description

Anorexia nervosa (AN) mainly affects young people, especially young women. AN is one of the most lethal psychiatric disorders. Treatment often proves to be very difficult, and AN course is frequently chronic. Specific pharmacological therapies for AN are lacking. Recent studies have shown that metabolic alterations play a great role in the etiology and pathogenesis of AN. An important metabolic alteration playing a role in the etiology and pathogenesis of AN is the hormone leptin. Patients with AN show hypoleptinemia. The role of hypoleptinemia in the neuroendocrine adaptation to starvation seems to induce emotional, cognitive, and behavioral symptoms of AN. From a theoretical point of view, pharmacotherapy augmenting leptin levels in patients with AN have a great therapeutic potential. Recently, positive effects with experimental administration of subcutaneous metreleptin in few young patients with severe AN have been observed. Importantly, no side effects have been observed. For all these reasons, the present study will investigate - with a double blind design - the therapeutic effect of metreleptin in patients with AN. Metreleptin will be administrated to 50 AN-inpatients: 25 patients will receive verum and 25 will receive placebo during 14 days. Primary objectives of this study are the amelioration of mood and weight. Secondary objectives are the investigation of functional brain connectivity, AN symptoms, as well as hematologic, blood chemistry and neuroendocrinological hormones. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06305182
Study type	Interventional
Source	University of Zurich
Contact	Gabriella Milos, Prof. Dr. med.
Phone	0041 44 255 52 80
Email	Gabriella.Milos@usz.ch
Status	Not yet recruiting
Phase	Phase 2
Start date	April 1, 2024
Completion date	February 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05531604` - Appetitive Conditioning in Anorexia Nervosa
Enrolling by invitation	`NCT04174703` - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing	N/A
Active, not recruiting	`NCT04883554` - Impact of an Olfactory Sensory Therapeutic Group for Adolescent Patients With Restrictive Anorexia Nervosa , Pilot Study	N/A
Recruiting	`NCT04213820` - TMS and Body Image Treatment for Anorexia Nervosa	N/A
Completed	`NCT03414112` - The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa	Early Phase 1
Recruiting	`NCT06144905` - Norwegian Microbiota Study in Anorexia Nervosa
Not yet recruiting	`NCT06380257` - Anorexia Nervosa and Brain in Adolescence
Not yet recruiting	`NCT05682417` - Impact of Body Schema Distortion on Remission and Weight Regain in Anorexia Nervosa	N/A
Not yet recruiting	`NCT05632497` - Alteration of Symbiosis Intestinal Microbiota on Patients With Anorexia Nervosa
Not yet recruiting	`NCT04804800` - Virtual Reality Place in the Management of Body Dysmorphia Disorders in Anorexia Nervosa	N/A
Not yet recruiting	`NCT03600610` - Evaluation of CARdiac Abnormalities by Echocardiography and MRI in Malnourished Patients Suffering From Anorexia Nervosa	N/A
Completed	`NCT02745067` - Effectiveness of Enhanced Cognitive Behavioral Therapy (CBT-E) in the Treatment of Anorexia Nervosa	N/A
Completed	`NCT02382055` - Changing Habits in Anorexia Nervosa: Novel Treatment Development	N/A
Completed	`NCT03075371` - Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa	N/A
Terminated	`NCT02240797` - Kappa Opioid Receptor Imaging in Anorexia	N/A
Completed	`NCT03144986` - Insula-coil Deep TMS for Treatment Resistant Anorexia Nervosa	N/A
Unknown status	`NCT01761942` - Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa	Phase 2
Completed	`NCT01579682` - Adaptive Family Treatment for Adolescent Anorexia Nervosa	N/A
Completed	`NCT02551445` - A fMRI Pilot Study of the Effects of Meal-support in Eating Disorders.	N/A
Completed	`NCT00946816` - The Effects of Dietary Intervention on Gastrointestinal Function in Patients With Anorexia Nervosa and Obesity	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Metreleptin in Anorexia Nervosa — METRAN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms